At present, the situation of diabetes prevention and control in China is very serious, and there is an urgent need to shift from the “blood glucose-centered” management model to an integrated management and control model in the standard treatment of diabetes. In addition, the 12-month results of the “3B Extension Project” also clearly indicate that the risk of cardiovascular disease can only be reduced by early joint intervention of patients’ blood pressure, lipid and blood glucose levels. Diabetes “equals” cardiovascular disease and other critical conditions, and it is urgent to establish an integrated management model. Studies have shown that the risk of cardiovascular disease is 2-4 times higher in diabetic patients with concomitant hypertension and hyperlipidemia than in diabetic patients without blood pressure or dyslipidemia.2 Diabetes is an equivocal risk for cardiovascular disease (CVD). However, traditional diabetes management in China is mainly focused on glycemic control, and in the realistic treatment environment, there is a lack of large and representative data to support the control of blood pressure, lipids, and glycemia and the corresponding treatment modalities for Chinese diabetic patients. And the effective development and implementation of the 3B study has well filled this clinical gap.” Prof. Lignon Ji pointed out. The 3B study is a prospective, non-interventional, cross-sectional survey study of current patients with type 2 diabetes in China. Fully conducted from 2010 to 2012, the study covered 104 hospitals in six geographic regions of China, enrolled 25,817 patients with type 2 diabetes, and involved 730 investigators from different levels of hospitals and disciplines, making it one of the largest, most comprehensively evaluated, and most representative effectiveness research projects in the field in China to date. It is understood that the results of this study, which has received widespread attention and high recognition in the academic community at home and abroad, have been included in the American Journal of Medicine (Am J Med) and will be officially published in May 2013. The results of the 3B study found that only 27.9% of type 2 diabetic patients had diabetes alone, while 30.1% had diabetes with hypertension, 12.2% had diabetes with dyslipidemia, and 29.7% had diabetes, hypertension and dyslipidemia at the same time. 29.7%. This indicates that more than 70% of diabetic patients have “two highs” or “three highs” at the same time. However, in the face of such a dilemma, the status of comprehensive prevention and control of diabetes is not optimistic. According to the standards set by the 2010 Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes, more than half of the diabetic patients in the survey had substandard blood glucose control, and only 5.6% of the patients had standard blood pressure, lipid and blood glucose control. The 3B study presents a true and comprehensive picture of the overall control status of diabetes and the problems in disease management in China. At present, there is an urgent clinical need to control the ‘three highs’ status of blood pressure, blood lipids and blood glucose in diabetic patients through translational medical research and the establishment of a multidisciplinary management model, which is of great significance for the future exploration and promotion of standardized diabetes management. It is reported that the 3B study, in addition to understanding the current status of diabetic patients’ blood pressure, lipid and blood glucose standards, also took a comprehensive look at the current clinical treatment models used to control the “three highs”. In addition, only 42.9% of diabetic patients received anti-hypertensive therapy and 23.1% received lipid-regulating therapy, and the patterns of anti-hypertensive and lipid-regulating therapy were significantly different from the guideline recommendations. To further observe the occurrence of cardiovascular events and diabetic complications in patients with substandard blood pressure, lipid and glucose levels, the expert committee of the CCMR study series also initiated the 3B extension project. This project selected 5,000 patients with at least 2 cardiovascular risk factors from the 3B study for a 3-year non-interventional follow-up. The proportion of patients with cardiovascular events was found to be 3.5% at the completed 12-month observation, while the proportion with diabetic microvascular and macrovascular complications was 8.1%. The results of the 3B extension project suggest that failure to intervene early in the blood pressure, lipid and glucose levels of diabetic patients will greatly increase the incidence of cardiovascular and cerebrovascular disease, posing a serious threat to patients’ lives and quality of life, as well as imposing a heavy economic burden on their families and society. For the majority of diabetic patients, only by recognizing the importance of controlling the ‘three highs’ as early as possible, enhancing awareness of the disease and self-management, adopting a scientific and reasonable lifestyle and active and effective drug interventions, can we effectively improve the prognosis of the disease and improve the quality of life. He also called on all sectors of society to pay attention and work together to strengthen education and training for primary care physicians on guidelines through government policy guidance, and actively develop community health services; at the same time, promote standardized treatment and comprehensive intervention for diabetes among both doctors and patients to delay and prevent the occurrence and development of diabetes complications, thus further improving public health and maximizing the savings of social medical resources. The 3B study was conducted over a two-year period and was initiated by the Chinese Gerontological Society, the expert committee of the CCMR series, and sponsored exclusively by Merck Sharp & Dohme, under the initiative of the Chinese Medical Association.